Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Linda Rubinstein was appointed as interim Chief Financial Officer at NEKTAR THERAPEUTICS.
- Action
- appointed
- Role
- interim Chief Financial Officer
Exact text from the filing
Effective May 15, 2026, Linda Rubinstein, a partner of FLG, will serve as the interim Chief Financial Officer and the principal financial and accounting officer of the Company.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Sandra Gardiner departed as interim Chief Financial Officer at NEKTAR THERAPEUTICS.
- Action
- retiring and stepping down
- Role
- interim Chief Financial Officer
Exact text from the filing
On May 7, 2026, the Company announced that Sandra Gardiner will be retiring and stepping down as interim Chief Financial Officer of the Company, effective May 15, 2026.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
NEKTAR THERAPEUTICS entered into Equity Distribution Agreement with Guggenheim Securities, LLC and H.C. Wainwright & Co., LLC valued at $150,000,000 (effective 2026-05-08).
- Action
- entry
- Agreement
- atm program
- Counterparty
- Guggenheim Securities, LLC and H.C. Wainwright & Co., LLC
- Value
- $150,000,000
- Effective
- 2026-05-08
Exact text from the filing
On May 8, 2026, Nektar Therapeutics (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”) with Guggenheim Securities, LLC (“Guggenheim Securities”) and H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”) having an aggregate offering price of up to $150,000,000 (the “Shares”), through Guggenheim Securities and Wainwright as its sales agents.
View on SEC.gov